Compare TLIH & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLIH | ASBP |
|---|---|---|
| Founded | 1998 | 2021 |
| Country | Singapore | United States |
| Employees | 62 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 7.6M |
| IPO Year | N/A | N/A |
| Metric | TLIH | ASBP |
|---|---|---|
| Price | $0.24 | $0.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 90.4K | ★ 523.9K |
| Earning Date | 05-01-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.05 |
| 52 Week High | $7.00 | $2.45 |
| Indicator | TLIH | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 36.03 |
| Support Level | $0.22 | $0.55 |
| Resistance Level | $0.52 | $0.88 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 42.03 | 2.15 |
Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental and provision of engineering consultancy services to port, construction, civil engineering and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment and port machinery. The company operates in Singapore and Other International Countries.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.